Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: UTR033
MIFTS: 51

Uterine Corpus Cancer

Categories: Cancer diseases, Reproductive diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Uterine Corpus Cancer

About this section

MalaCards integrated aliases for Uterine Corpus Cancer:

Name: Uterine Corpus Cancer 12 15 73
Malignant Uterine Corpus Neoplasm 73
Corpus Uteri Cancer 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:9460
ICD10 33 C54 C54.9
ICD9CM 35 182
NCIt 50 C3556
Sources

Summaries for Uterine Corpus Cancer

About this section
Disease Ontology : 12 A uterine cancer that is located in the uterine corpus.

MalaCards based summary : Uterine Corpus Cancer, also known as malignant uterine corpus neoplasm, is related to uterine corpus serous adenocarcinoma and uterine body mixed cancer. An important gene associated with Uterine Corpus Cancer is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Endometrial cancer and Glioma. The drugs Peppermint and Hormones have been mentioned in the context of this disorder. Affiliated tissues include the uterine corpus, lymph node and uterus, and related phenotypes are cellular and homeostasis/metabolism

Sources

Related Diseases for Uterine Corpus Cancer

About this section

Diseases related to Uterine Corpus Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 136)
# Related Disease Score Top Affiliating Genes
1 uterine corpus serous adenocarcinoma 32.2 ERBB2 KIAA1324 TP53
2 uterine body mixed cancer 31.5 ERBB2 PGR PIK3R2 TP53
3 endometrial cancer 29.2 ERBB2 ESR1 MYC PGR PIK3R2 S100A6
4 uterine corpus endometrial carcinoma 11.1
5 uterine corpus sarcoma 11.1
6 gallbladder squamous cell carcinoma 10.8 ERBB2 TP53
7 gastric papillary adenocarcinoma 10.8 ERBB2 TP53
8 vulva basal cell carcinoma 10.8 ERBB2 MYC
9 non-proliferative fibrocystic change of the breast 10.8 ERBB2 TP53
10 pleomorphic adenoma carcinoma 10.7 ERBB2 TP53
11 fallopian tube adenocarcinoma 10.7 ERBB2 TP53
12 glioma susceptibility 1 10.7 ERBB2 TP53
13 oral leukoplakia 10.7 ERBB2 TP53
14 b cell prolymphocytic leukemia 10.7 MYC TP53
15 megaesophagus 10.7 MYC TP53
16 endometrium carcinoma in situ 10.6 PGR TP53
17 scirrhous adenocarcinoma 10.6 ERBB2 PGR
18 breast apocrine carcinoma 10.6 ERBB2 PGR
19 suppressor of tumorigenicity 3 10.6 MYC TP53
20 breast mucoepidermoid carcinoma 10.6 ERBB2 PGR
21 ovary adenocarcinoma 10.6 ERBB2 TP53
22 breast metaplastic carcinoma 10.6 ERBB2 PGR
23 female reproductive endometrioid cancer 10.6 PGR TP53
24 breast malignant phyllodes tumor 10.6 PGR TP53
25 intracystic papillary adenoma 10.6 ERBB2 PGR
26 olfactory groove meningioma 10.6 PGR TP53
27 progesterone-receptor negative breast cancer 10.6 ERBB2 PGR
28 richter's syndrome 10.5 MYC TP53
29 papillary serous adenocarcinoma 10.5 PGR TP53
30 anterior cranial fossa meningioma 10.5 PGR TP53
31 esophagus adenocarcinoma 10.5 ERBB2 MYC TP53
32 cerebral primitive neuroectodermal tumor 10.5 MYC TP53
33 endometrial clear cell adenocarcinoma 10.4 ESR1 TP53
34 respiratory system cancer 10.4 ERBB2 MYC TP53
35 gastrointestinal system cancer 10.4 ERBB2 MYC TP53
36 pancreas adenocarcinoma 10.4 ERBB2 MYC TP53
37 papillary hidradenoma 10.4 PGR S100A6
38 granulosa cell tumor of the ovary 10.4 ERBB2 TP53
39 comedo carcinoma 10.4 ERBB2 ESR1
40 breast secretory carcinoma 10.3 ERBB2 PGR
41 breast squamous cell carcinoma 10.3 ERBB2 PGR TP53
42 microglandular adenosis 10.3 ERBB2 PGR TP53
43 primary peritoneal carcinoma 10.3 ERBB2 PGR TP53
44 papillary adenocarcinoma 10.3 ERBB2 PGR TP53
45 malignant ovarian surface epithelial-stromal neoplasm 10.3 ERBB2 PGR TP53
46 serous cystadenocarcinoma 10.3 ERBB2 PGR TP53
47 cystadenocarcinoma 10.3 ERBB2 PGR TP53
48 ovarian serous cystadenocarcinoma 10.3 ERBB2 PGR TP53
49 vulvar syringoma 10.2 ESR1 PGR
50 lung leiomyoma 10.2 ESR1 PGR

Graphical network of the top 20 diseases related to Uterine Corpus Cancer:



Diseases related to Uterine Corpus Cancer
Sources

Symptoms & Phenotypes for Uterine Corpus Cancer

About this section

MGI Mouse Phenotypes related to Uterine Corpus Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.06 GATM KIAA1324 ERBB2 MYC NCAPH ESR1
2 homeostasis/metabolism MP:0005376 10.06 PIK3R2 S100A6 KIAA1324 ERBB2 MYC ESR1
3 endocrine/exocrine gland MP:0005379 9.98 S100A6 ERBB2 MYC ESR1 PGR GATM
4 mortality/aging MP:0010768 9.91 S100A6 KIAA1324 ERBB2 MYC NCAPH ESR1
5 integument MP:0010771 9.85 GATM ERBB2 MYC ESR1 PGR TP53
6 limbs/digits/tail MP:0005371 9.72 ERBB2 MYC ESR1 PGR TP53
7 muscle MP:0005369 9.7 ERBB2 MYC ESR1 PGR GATM PIK3R2
8 neoplasm MP:0002006 9.43 ERBB2 MYC ESR1 PGR PIK3R2 TP53
9 reproductive system MP:0005389 9.23 S100A6 KIAA1324 ERBB2 MYC ESR1 PGR
Sources

Drugs & Therapeutics for Uterine Corpus Cancer

About this section

Drugs for Uterine Corpus Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 328)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Peppermint Approved, Nutraceutical Phase 4
2 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
3 taxane Phase 4,Phase 1
4 Fluorodeoxyglucose F18 Phase 4,Phase 2,Phase 1,Not Applicable
5
Menthol Approved Phase 3,Not Applicable 2216-51-5 16666
6
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
7
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
8
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
9
Progesterone Approved, Vet_approved Phase 3,Phase 2,Phase 1 57-83-0 5994
10
Megestrol acetate Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1 595-33-5 11683
11
Levonorgestrel Approved, Investigational Phase 3,Phase 2,Not Applicable 797-63-7, 17489-40-6 13109
12
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
13
Medroxyprogesterone acetate Approved, Investigational Phase 3,Phase 2 71-58-9
14
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
15
Metformin Approved Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1,Not Applicable 657-24-9 14219 4091
16
Methylene blue Approved, Investigational Phase 3 61-73-4
17
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
18
Ifosfamide Approved Phase 3 3778-73-2 3690
19
Exemestane Approved, Investigational Phase 3,Phase 2,Not Applicable 107868-30-4 60198
20
Tamoxifen Approved Phase 3,Phase 2,Phase 1 10540-29-1 2733526
21
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
22
Epirubicin Approved Phase 3 56420-45-2 41867
23
Aspirin Approved, Vet_approved Phase 3,Phase 2 50-78-2 2244
24
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 77-92-9 311
25
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
26
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
27
Pyridoxal Approved, Nutraceutical Phase 3 66-72-8 1050
28
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 9860744
29
Genistein Investigational Phase 3,Phase 1 446-72-0 5280961
30
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
31 Progestins Phase 3,Phase 2,Phase 1
32 Epothilones Phase 3,Phase 2,Phase 1
33
Medroxyprogesterone Phase 3,Phase 2 520-85-4 10631
34
Megestrol Phase 2, Phase 3,Phase 3,Phase 1 3562-63-8 19090 3080587
35 Alkylating Agents Phase 3,Phase 2,Phase 1
36 Fibrin fragment D Phase 3
37 Central Nervous System Stimulants Phase 2, Phase 3,Phase 3,Phase 1
38 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
39 Steroid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
40 Contraceptive Agents Phase 3,Phase 2,Phase 1,Not Applicable
41 Contraceptive Agents, Male Phase 3,Phase 2
42 Contraceptives, Oral Phase 3,Phase 2,Phase 1,Not Applicable
43 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
44 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
46 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
47 Vitamin B Complex Phase 3,Phase 2,Phase 1
48 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
49 Estrogen Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
50 Estrogens Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 634)
# Name Status NCT ID Phase Drugs
1 Upper Vaginectomy Versus Brachytherapy in Patients With Early Stage Endometrial Cancer Treated With Laparoscopic Surgery Unknown status NCT00719017 Phase 4
2 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
3 A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment Completed NCT00190697 Phase 4 arzoxifene
4 Biomarker Guided Treatment in Gynaecological Cancer Recruiting NCT02543710 Phase 4 Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
5 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Not yet recruiting NCT03349463 Phase 4 Fluciclovine F18
6 Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer. Not yet recruiting NCT03423082 Phase 4 18F fluciclovine
7 Role of Uterine Manipulator in Hysterectomy - Ro.Man.HY Unknown status NCT02762214 Phase 3
8 Effects of the Concentrated Extract of Soy on Coagulation Factors After Menopause Unknown status NCT00925639 Phase 3 Isoflavone;Placebo
9 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
10 Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer Completed NCT01767155 Phase 3 AEZS-108 / zoptarelin doxorubicin;doxorubicin
11 Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer Completed NCT00003749 Phase 3
12 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
13 External-Beam Radiation Therapy Compared With Vaginal Brachytherapy After Surgery for Stage I Endometrial Cancer Completed NCT00376844 Phase 3
14 Indocyanine Green Versus Blue Dye for Detection of Sentinel Lymph Node In Endometrial Cancer Completed NCT02564276 Phase 3
15 Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery Completed NCT00002807 Phase 3
16 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
17 Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Completed NCT00003691 Phase 3 cisplatin;doxorubicin hydrochloride;paclitaxel
18 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
19 Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus Completed NCT00002706 Phase 3
20 Tachosil for the Prevention of Symptomatic Lymph Cysts Completed NCT01470677 Phase 3 Tachosil fibrin patch
21 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
22 S9630, Medroxyprogesterone in Treating Women With Breast Cancer Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate
23 Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus Completed NCT00002459 Phase 3
24 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer Completed NCT00245050 Phase 3 Placebo;doxorubicin HCL liposome
25 Resectoscopic Treatment of Atypical Endometrial Polyps in Fertile Women Completed NCT00490087 Phase 3
26 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
27 Pelvic Drains After Radical Hysterectomy in Treating Patients With Uterine, Cervical, or Vaginal Cancer Completed NCT00003267 Phase 3
28 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
29 Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis Completed NCT00033605 Phase 3 octreotide acetate
30 Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane Completed NCT00036270 Phase 3 exemestane (Aromasin);tamoxifen + exemestane
31 Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women Completed NCT00003906 Phase 3 Raloxifene;Tamoxifen
32 Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis Completed NCT00670319 Phase 3 Raloxifene HCL;Raloxifene HCL;Placebo
33 Maintenance With Selinexor/Placebo After Combination Chemotherapy in Endometrial Cancer. Recruiting NCT03555422 Phase 3 Selinexor;Placebo
34 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
35 Megestrol Acetate Plus LNG-IUS in Young Women With Early Endometrial Cancer Recruiting NCT03241914 Phase 2, Phase 3 Megestrol Acetate
36 Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC Recruiting NCT03463252 Phase 2, Phase 3 Progesterone;GnRH agonist
37 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
38 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
39 Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Active, not recruiting NCT00063999 Phase 3 Carboplatin;Cisplatin;Doxorubicin Hydrochloride;Paclitaxel
40 An Endometrial Cancer Chemoprevention Study of Metformin Active, not recruiting NCT01697566 Phase 3 Metformin
41 Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer Active, not recruiting NCT00411138 Phase 3 cisplatin;carboplatin;Paclitaxel
42 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
43 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
44 Laparoscopic Approach to Cancer of the Endometrium Active, not recruiting NCT00096408 Phase 3
45 Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia Active, not recruiting NCT01357772 Phase 3 Tamoxifen;placebo
46 Oral Micronized Progesterone for Perimenopausal Vasomotor Symptoms Active, not recruiting NCT01464697 Phase 3 Oral micronized progesterone;placebo
47 Phase III, Randomized, Double Blind Trial Low Dose Tamoxifen Versus Placebo in Hormone Replacement Therapy (HRT) Users Active, not recruiting NCT01579734 Phase 3 Tamoxifen;Placebo
48 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Active, not recruiting NCT01672892 Phase 3
49 Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms Active, not recruiting NCT01376349 Phase 3 prasterone
50 VIrtual REality Glasses for the Enhancement of Acute BRACHYtherapy Tolerance for Endometrial Cancer Patients. Not yet recruiting NCT03324958 Phase 3

Search NIH Clinical Center for Uterine Corpus Cancer

Sources

Genetic Tests for Uterine Corpus Cancer

About this section
Sources

Anatomical Context for Uterine Corpus Cancer

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Uterine Corpus Cancer:

19
The Uterine Corpus

MalaCards organs/tissues related to Uterine Corpus Cancer:

41
Lymph Node, Uterus, Testes, Colon, Cervix, Bone, Prostate
Sources

Publications for Uterine Corpus Cancer

About this section

Articles related to Uterine Corpus Cancer:

(show all 29)
# Title Authors Year
1
Need for an up to date and comprehensive risk factor analysis to determine the lifetime risk of uterine corpus cancer in Taiwan women. ( 28805629 )
2017
2
Reply to "Need for an up to date and comprehensive risk factor analysis to determine the lifetime risk of uterine corpus cancer in Taiwan women". ( 28805626 )
2017
3
Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement. ( 27894165 )
2017
4
Incidence and lifetime risk of uterine corpus cancer in Taiwanese women from 1991 to 2010. ( 28254229 )
2017
5
Laparoscopic Repair of Vaginal Evisceration after Abdominal Hysterectomy for Uterine Corpus Cancer: A Case Report and Literature Review. ( 28502966 )
2017
6
A prediction model of survival for patients with bone metastasis from uterine corpus cancer. ( 27655906 )
2016
7
Lymphovascular space invasion in uterine corpus cancer: What is its prognostic significance in the absence of lymph node metastases? ( 27261326 )
2016
8
Genitofemoral neuropathy after pelvic lymphadenectomy in patients with uterine corpus cancer. ( 25486104 )
2015
9
Comorbidity is an independent prognostic factor in women with uterine corpus cancer: a nationwide cohort study. ( 24443826 )
2014
10
State-level uterine corpus cancer incidence rates corrected for hysterectomy prevalence, 2004 to 2008. ( 23125334 )
2013
11
Efficacy of para-aortic lymphadenectomy in early-stage endometrioid uterine corpus cancer. ( 21136177 )
2011
12
Comparative performance of the 2009 International Federation of Gynecology and Obstetrics' staging system for uterine corpus cancer. ( 21508766 )
2011
13
Comparative Performance of the 2009 International Federation of Gynecology and Obstetrics' Staging System for Uterine Corpus Cancer. ( 21705925 )
2011
14
Comparative performance of the 2009 international Federation of gynecology and obstetrics' staging system for uterine corpus cancer. ( 20966700 )
2010
15
Comparison of second cancer risks from brachytherapy and external beam therapy after uterine corpus cancer. ( 20142245 )
2010
16
Current status in the management of uterine corpus cancer in Korea. ( 20922137 )
2010
17
Evaluation of FDG-PET for detecting lymph node metastasis in uterine corpus cancer. ( 20944170 )
2010
18
Positron emission tomography with the glucose analog [F]-fluoro-2-deoxy-D-glucose for evaluating pelvic lymph node metastasis in uterine corpus cancer: comparison with CT and MRI findings. ( 19215544 )
2009
19
Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer. ( 18064567 )
2008
20
Comparison of the validity of magnetic resonance imaging and positron emission tomography/computed tomography in the preoperative evaluation of patients with uterine corpus cancer. ( 18201753 )
2008
21
FDG PET for the assessment of myometrial infiltration in clinical stage I uterine corpus cancer. ( 16710101 )
2006
22
The use of adjuvant radiation therapy in patients with intermediate-risk Stages IC and II uterine corpus cancer: a patient care evaluation study from the American College of Surgeons National Cancer Data Base. ( 16198401 )
2005
23
Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. ( 15581961 )
2004
24
Ethnic differences in uterine corpus cancer incidence and mortality in New Mexico's American Indians, hispanics and non-Hispanic whites. ( 9169158 )
1997
25
Identification of TP53 gene mutations in uterine corpus cancer with short follow-up. ( 9441778 )
1997
26
Correlation of C-myc and HER-2/neu amplification and expression with histopathologic variables in uterine corpus cancer. ( 7977518 )
1994
27
Estriol binding in uterine corpus cancer and in normal uterine tissues. ( 1869022 )
1991
28
Height and weight in relation to uterine corpus cancer morbidity and mortality. A follow-up study of 570,000 women in Norway. ( 2384266 )
1990
29
A cohort analysis of breast cancer, uterine corpus cancer, and childbearing pattern in Norwegian women. ( 2273359 )
1990
Sources

Variations for Uterine Corpus Cancer

About this section

Copy number variations for Uterine Corpus Cancer from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 162862 22 22706138 22714284 Decreasing copy numb er GSTT1 Corpus uteri cancer
Sources

Expression for Uterine Corpus Cancer

About this section
Search GEO for disease gene expression data for Uterine Corpus Cancer.
Sources

Pathways for Uterine Corpus Cancer

About this section

Pathways related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

(show all 40)
# Super pathways Score Top Affiliating Genes
1
Endometrial cancer 37
Show member pathways
 12.72 ERBB2 MYC PIK3R2 TP53
2
Glioma 37
Show member pathways
 12.62 ERBB2 ESR1 PIK3R2 TP53
3
Pathways in cancer 37
12.61 ERBB2 ESR1 MYC PIK3R2 TP53
4
Development HGF signaling pathway 22
Show member pathways
 12.57 ERBB2 ESR1 PIK3R2 TP53
5
Immune response IL-23 signaling pathway 22
Show member pathways
 12.44 ERBB2 MYC PIK3R2 TP53
6
Development EGFR signaling pathway 22
Show member pathways
 12.39 ERBB2 MYC PIK3R2 TP53
7
MicroRNAs in cancer 37
12.34 ERBB2 MYC PIK3R2 TP53
8
Prolactin Signaling Pathway 1 37
Show member pathways
 12.31 ERBB2 ESR1 MYC PIK3R2
9
ErbB signaling pathway 1 37
Show member pathways
 12.3 ERBB2 MYC PIK3R2 TP53
10
Gastric cancer 37
Show member pathways
 12.3 ERBB2 ESR1 MYC PGR PIK3R2 TP53
11
Development Ligand-independent activation of ESR1 and ESR2 22
Show member pathways
 12.18 ERBB2 ESR1 PIK3R2
12
Epstein-Barr virus infection 37
12.16 MYC PIK3R2 TP53
13
Cell cycle Role of SCF complex in cell cycle regulation 22
Show member pathways
 12.09 ESR1 MYC PGR
14
Colorectal Cancer Metastasis 64
12.06 MYC PIK3R2 TP53
15
Cellular senescence (KEGG) 37
12.03 MYC PIK3R2 TP53
16
NGF Pathway 64
Show member pathways
 12 MYC PIK3R2 TP53
17
Development EGFR signaling via small GTPases 22
Show member pathways
 12 ERBB2 MYC PIK3R2
18
AKT Signaling Pathway 67
11.97 ERBB2 MYC PIK3R2 TP53
19
Integrated Breast Cancer Pathway 1
11.95 ESR1 MYC PIK3R2 TP53
20
TGF-beta Signaling Pathway (WikiPathways) 1
11.93 MYC PIK3R2 TP53
21
Development IGF-1 receptor signaling 22
Show member pathways
 11.9 MYC PIK3R2 TP53
22
MAPK Pathway 72
Show member pathways
 11.89 ERBB2 PIK3R2 TP53
23
Glioblastoma Multiforme 64
11.84 MYC PIK3R2 TP53
24
Signaling by ERBB4 66
Show member pathways
 11.82 ERBB2 ESR1 PGR
25
Thyroid hormone signaling pathway 37
11.77 ESR1 MYC PIK3R2 TP53
26
TGF-beta Signaling Pathways 65
11.75 ESR1 MYC PIK3R2
27
Small cell lung cancer 37
11.73 MYC PIK3R2 TP53
28
DNA Damage Response (only ATM dependent) 1
11.73 ERBB2 MYC PIK3R2 TP53
29
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors 66
Show member pathways
 11.72 ERBB2 ESR1 MYC
30
Platinum drug resistance 37
11.58 ERBB2 PIK3R2 TP53
31
Pathways Affected in Adenoid Cystic Carcinoma 1
11.52 ERBB2 MYC TP53
32
Bladder cancer 37 1
11.42 ERBB2 MYC PIK3R2 TP53
33
Proteoglycans in cancer 37
11.32 ERBB2 ESR1 MYC PIK3R2 TP53
34
LKB1 signaling events 1
11.28 ESR1 MYC TP53
35
Gastric Cancer Network 2 1
11.13 MYC S100A6 TP53
36
Apoptosis and survival_Anti-apoptotic action of nuclear ESR1 and ESR2 22
11.12 ESR1 MYC
37
Metastatic brain tumor 1
11.12 MYC TP53
38
Central carbon metabolism in cancer 37
11.07 ERBB2 MYC PIK3R2 TP53
39
TP53 Network 1
Show member pathways
 11 MYC TP53
40
Inhibition of Ribosome Biogenesis by p14(ARF) 64
10.84 MYC PIK3R2 TP53
Sources

GO Terms for Uterine Corpus Cancer

About this section

Biological processes related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.77 ESR1 MYC PGR PIK3R2 TP53
2 positive regulation of protein kinase B signaling GO:0051897 9.5 ERBB2 ESR1 PIK3R2
3 negative regulation of fibroblast proliferation GO:0048147 9.46 MYC TP53
4 phosphatidylinositol 3-kinase signaling GO:0014065 9.43 ERBB2 PIK3R2
5 response to gamma radiation GO:0010332 9.4 MYC TP53
6 cellular response to estrogen stimulus GO:0071391 9.26 ESR1 MYC
7 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.16 ESR1 TP53
8 phosphatidylinositol phosphorylation GO:0046854 9.13 ERBB2 ESR1 PIK3R2
9 positive regulation of fibroblast proliferation GO:0048146 8.8 ESR1 MYC S100A6

Molecular functions related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.56 ERBB2 MYC PIK3R2 TP53
2 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.46 ESR1 MYC PGR TP53
3 steroid binding GO:0005496 9.32 ESR1 PGR
4 protein phosphatase binding GO:0019903 9.13 ERBB2 PIK3R2 TP53
5 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.8 ERBB2 ESR1 PIK3R2
Sources

Sources for Uterine Corpus Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....